X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://endpts.com/bellerophon-therapeutics-lets-almost-all-employees-go-looks-for-deals-in-wake-of-phiii-flop/
https://www.clinicaltrialsarena.com/news/bellerophon-therapeutics-fild-trial/
https://endpts.com/bellerophon-therapeutics-drug-device-fails-another-phiii-in-lung-disease-stock-implodes/
https://www.globenewswire.com/news-release/2023/06/05/2681822/0/en/Bellerophon-Announces-Top-Line-Data-from-Phase-3-REBUILD-Clinical-Trial-of-INOpulse-for-Treatment-of-Fibrotic-Interstitial-Lung-Disease.html
https://www.globenewswire.com/news-release/2023/05/15/2669391/0/en/Bellerophon-Provides-Clinical-Program-Update-and-Reports-First-Quarter-2023-Financial-Results.html
https://www.globenewswire.com/news-release/2023/05/11/2666738/0/en/Bellerophon-Therapeutics-Announces-Last-Patient-Has-Completed-Blinded-Treatment-in-Phase-3-REBUILD-Study-for-INOpulse-in-Fibrotic-Interstitial-Lung-Disease.html
https://www.globenewswire.com/news-release/2023/03/31/2638625/0/en/Bellerophon-Provides-Clinical-Program-Update-and-Reports-Full-Year-2022-Financial-Results.html
https://www.globenewswire.com/news-release/2023/03/06/2621122/0/en/Bellerophon-Therapeutics-Announces-5-Million-Registered-Direct-Offering.html
https://www.globenewswire.com/news-release/2023/02/09/2605021/0/en/Bellerophon-Therapeutics-Receives-IND-Clearance-from-China-NMPA-to-Conduct-Phase-3-Clinical-Trial-in-China-for-INOpulse-in-Fibrotic-Interstitial-Lung-Disease.html
https://www.clinicaltrialsarena.com/news/bellerophon-enrollment-inopulse-trial/
Market Place
Share 
